A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection

Autor: Lukas K. van Vugt, Marieke van der Zwan, Marian C. Clahsen-van Groningen, Madelon van Agteren, Daphne M. Hullegie-Peelen, Brenda C. M. De Winter, Marlies E. J. Reinders, Pedro Miranda Afonso, Dennis A. Hesselink

Publikováno v: Transplant International, Vol 36 (2023)

Alemtuzumab is used as lymphocyte-depleting therapy for severe or glucocorticoid-resistant kidney transplant rejection. However, the long-term efficacy and toxicity of alemtuzumab therapy are unclear. Therefore, all cases of alemtuzumab anti-rejectio

Externí odkaz: https://doaj.org/article/cfd685a2a41d4895a6c64720351229a2

Investigational drugs for the treatment of kidney transplant rejection

Autor: Lukas K van Vugt, Maaike R Schagen, Annelies de Weerd, Marlies EJ Reinders, Brenda CM de Winter, Dennis A Hesselink

Publikováno v: Expert opinion on investigational drugs. 31(10)

Introduction: Kidney transplant rejection remains an important clinical problem despite the development of effective immunosuppressive therapy. Two major types of rejection are recognized, T-cell-mediated rejection (TCMR) and antibody-mediated reject

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a54074bc40e43ce71782106df3a79c10
https://pubmed.ncbi.nlm.nih.gov/36175360

[Acute kidney injury, an avoidable problem].

Autor: van Vugt LK; Amphia Ziekenhuis, afd. Interne Geneeskunde, Breda.; Contact: Lukas K. van Vugt (lvanvugt@amphia.nl)., Wagenaar E; Amphia Ziekenhuis, afd. Interne Geneeskunde, Breda., van Etten RW; Amphia Ziekenhuis, afd. Interne Geneeskunde, Breda.

Publikováno v: Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 2021 Apr 08; Vol. 165. Date of Electronic Publication: 2021 Apr 08.